Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

Historically an active player in the M&A space, Radnor-based Avantor has not found itself so busy in that realm during the ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...

The stock is currently at ~$190. There was a ~10% further increase over the last two quarters. Johnson & Johnson (JNJ): JNJ ...